Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 32

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Antisuicide Properties of Psychotropic Drugs: A Critical Review

Ernst, Carrie L., Goldberg, Joseph F.·2004·Harvard Review of Psychiatry
DOI 10.1080/10673220490425924
Open this paper in CoChat — free account

Abstract

The authors consider the extent to which psychotropic medications demonstrate benefits in the prevention of suicidal behavior in psychiatric patients. Results of a MedLine search are critically reviewed for lithium, divalproex and other anticonvulsants, conventional and atypical antipsychotics, and antidepressants. The existing literature is almost entirely limited to noncontrolled, often retrospective studies that do not control for potential biases in treatment selection, the use of multiple medications, the impact of medication nonadherence, and nonrandomized treatment discontinuations. Nevertheless, an extensive literature has arisen regarding observed reductions in suicidal behavior with lithium for mood disorders and, to a lesser extent, with clozapine for schizophrenia. A substantially smaller literature suggests more negative than positive data with divalproex or carbamazepine in bipolar disorder, while minimal information exists regarding suicidality with atypical antipsychotics other than clozapine. Studies of antidepressants have mostly been short-term and have focused more on whether they induce (rather than ameliorate) suicidal thoughts or behaviors. The sum of existing studies is generally inconclusive about whether antidepressants appreciably reduce risk for suicide completions. Relatively little is known about pharmacotherapy effects on suicidal ideation as distinct from behaviors. Possible mechanistic considerations for understanding antisuicide properties in…

Overview

Integrity signals

Registry

Crossref · 10.1080/10673220490425924

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 5 references

Research works printed but not linked: 177

  1. Gunnell, 1994, Prevention of suicide: aspirations and evidence., BMJ, 308, 1227, 10.1136/bmj.308.6938.1227 · DOI · Paper page
  2. Tondo, 2001, Lower suicide risk with long-term lithium treatment in major affective illness: a meta-analysis., Acta Psychiatr Scand, 104, 163, 10.1034/j.1600-0447.2001.00464.x · DOI · Paper page
  3. Meltzer, 1999, Suicide and schizophrenia: clozapine and the InterSePT study., J Clin Psychiatry, 60, 47
  4. Van Praag, 2002, Why has the antidepressant era not shown a significant drop in suicide rates., Crisis, 23, 77, 10.1027//0227-5910.23.2.77 · DOI
  5. Pincus, 1998, Prescribing trends in psychotropic medications., JAMA, 279, 526, 10.1001/jama.279.7.526 · DOI · Paper page
  6. Isacsson, 1996, Epidemiological data suggest antidepressants reduce suicide risk among depressives., J Affect Disord, 41, 1, 10.1016/0165-0327(96)00050-X · DOI
  7. Isacsson, 2000, Suicide preventiona medical breakthrough., Acta Psychiatr Scand, 102, 113, 10.1034/j.1600-0447.2000.102002113.x · DOI · Paper page
  8. Ohberg, 1998, Antidepressants and suicide mortality., J Affect Disord, 50, 225, 10.1016/S0165-0327(98)00114-1 · DOI
  9. Carlsten, 2001, Antidepressant medication and suicide in Sweden., Pharmacoepidemiol Drug Saf, 10, 525, 10.1002/pds.618 · DOI
  10. Rihmer, 2000, Decreasing suicide in Hungary Letter., Br J Psychiatry, 177, 84, 10.1192/bjp.177.1.84 · DOI
  11. Barbui, 1999, Antidepressant drug use in Italy since the introduction of SSRIs: national trends, regional differences and impact on suicide rates., Soc Psychiatry Psychiatr Epidemiol, 34, 152, 10.1007/s001270050127 · DOI
  12. Olfson, 2003, Relationship between antidepressant medication treatment and suicide in adolescents., Arch Gen Psychiatry, 60, 978, 10.1001/archpsyc.60.9.978 · doi:10.1001/archpsyc.60.9.978 · Paper page
  13. De Leo, 2002, Why are we not getting any closer to preventing suicide., Br J Psychiatry, 181, 372, 10.1192/bjp.181.5.372 · DOI
  14. Rutz, 1989, Frequency of suicide in Gotland after systematic postgraduate education of general practitioners., Acta Psychiatr Scand, 80, 151, 10.1111/j.1600-0447.1989.tb01318.x · DOI · Paper page
  15. Baldessarini, 2001, Treating the suicidal patient with bipolar disorder. Reducing suicide risk with lithium., Ann NY Acad Sci, 932, 24, 10.1111/j.1749-6632.2001.tb05796.x · DOI
  16. Baca-Garcia, 2001, A prospective study of the paradoxical relationship between impulsivity and lethality of suicide attempts., J Clin Psychiatry, 62, 560, 10.4088/JCP.v62n07a11 · DOI
  17. Rifkin, 1972, Lithium carbonate in emotionally unstable character disorder., Arch Gen Psychiatry, 27, 519, 10.1001/archpsyc.1972.01750280083014 · DOI
  18. Wickham, 1977, Lithium for the control of aggressive and self-mutilating behavior., Int Clin Psychopharmacol, 2, 181, 10.1097/00004850-198707000-00001 · DOI
  19. Tondo, 1998, Lithium treatment and risk of suicidal behavior in bipolar disorder patients., J Clin Psychiatry, 59, 404, 10.4088/JCP.v59n0802 · DOI
  20. Van Praag, 1992, Depression, aggression, and anxiety: a biological hypothesis about their interrelation., Eur Neuropsychopharmacol, 2, 393
  21. Schou, 1998, The effect of prophylactic lithium treatment on mortality and suicidal behavior: a review for clinicians., J Affect Disord, 50, 253
  22. Baldessarini, 2003, Lithium treatment and suicide risk in major affective disorders: update and new findings., J Clin Psychiatry, 64, 44
  23. Nilsson, 1999, Lithium therapy and suicide risk., J Clin Psychiatry, 60, 85
  24. Muller-Oerlinghausen, 1996, Mortality of patients who dropped out from regular lithium prophylaxis: a collaborative study by the International Group for the Study of Lithium-Treated Patients (IGSLI)., Acta Psychiatr Scand, 94, 333, 10.1111/j.1600-0447.1996.tb09870.x · DOI
  25. Prien, 1974, J., Caffey EM. Lithium prophylaxis in recurrent affective illness., Am J Psychiatry, 131, 198, 10.1176/ajp.131.2.198 · DOI
  26. Thies-Flechtner, 1996, Effect of prophylactic treatment on suicide risk in patients with major affective disorder., Pharmacopsychiatry, 29, 103, 10.1055/s-2007-979553 · DOI
  27. Greil, 1993, Muller-Oerlinghausen, et al. The recruitment process for a multicenter study on the long-term prophylactic treatment of affective disorders., J Affect Disord, 28, 257, 10.1016/0165-0327(93)90061-N · DOI
  28. Greil, 1997, Lithium versus carbamazepine in the maintenance treatment of bipolar disordersa randomized study., J Affect Disord, 43, 151, 10.1016/S0165-0327(96)01427-9 · DOI · Paper page
  29. Goodwin, 2003, Suicide risk in bipolar disorder during treatment with lithium and divalproex., JAMA, 290, 1467, 10.1001/jama.290.11.1467 · DOI · Paper page
  30. Coryell, 2001, Lithium and suicidal behavior in major affective disorder: a case-control study., Acta Psychiatr Scand, 104, 193, 10.1034/j.1600-0447.2001.00338.x · DOI
  31. Muller-Oerlinghausen, 1992, The effect of long-term lithium treatment on the mortality of patients with manic-depressive and schizoaffective illness., Acta Psychiatr Scand, 86, 218, 10.1111/j.1600-0447.1992.tb03255.x · DOI · Paper page
  32. Muller-Oerlinghausen, 1994, Mortality during initial and during later lithium treatment., Acta Psychiatr Scand, 90, 295, 10.1111/j.1600-0447.1994.tb01596.x · DOI
  33. Coppen, 1991, Does lithium reduce the mortality of recurrent mood disorders., J Affect Disord, 23, 1, 10.1016/0165-0327(91)90030-V · DOI · Paper page
  34. Ahrens, 1995, Excess cardiovascular and suicide mortality of affective disorders may be reduced by lithium prophylaxis., J Affect Disord, 33, 67, 10.1016/0165-0327(94)00074-J · DOI
  35. Norton, 1984, Mortality of a lithium-treated population., Br J Psychiatry, 145, 277, 10.1192/bjp.145.3.277 · DOI
  36. Vestergaard, 1991, Five-year mortality in lithium-treated manic-depressive patients., J Affect Disord, 21, 33, 10.1016/0165-0327(91)90016-L · DOI
  37. Brodersen, 2000, Sixteen-year mortality in patients with affective disorder commenced on lithium., Br J Psychiatry, 176, 429, 10.1192/bjp.176.5.429 · DOI
  38. Ahrens, 2001, Does lithium exert an independent antisuicidal effect., Pharmacopsychiatry, 34, 132, 10.1055/s-2001-15878 · DOI
  39. Swann, 1997, Depression during mania. Treatment response to lithium or divalproex., Arch Gen Psychiatry, 54, 37, 10.1001/archpsyc.1997.01830130041008 · DOI · Paper page
  40. Bowden, 2003, Lamictal 606 Study Group. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder., Arch Gen Psychiatry, 60, 392, 10.1001/archpsyc.60.4.392 · DOI · Paper page
  41. Calabrese, 2003, Lamictal 605 Study Group. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder., J Clin Psychiatry, 64, 1013, 10.4088/JCP.v64n0906 · DOI · Paper page
  42. Tsai, 1999, Characteristics and psychosocial problems of patients with bipolar disorder at high risk for suicide attempt., J Affect Disord, 52, 145, 10.1016/S0165-0327(98)00066-4 · DOI
  43. Tondo, 1999, Suicide attempts in major affective disorder patients with comorbid substance use disorders., J Clin Psychiatry, 60, 63
  44. Yerevenian, 2003, Lithium, anticonvulsants and suicidal behavior in bipolar disorder., J Affect Disord, 73, 223, 10.1016/S0165-0327(02)00302-6 · DOI
  45. Cowdry, 1988, Pharmacotherapy of borderline personality disorder. Alprazolam, carbamazepine, trifluoperazine, and tranylcypromine., Arch Gen Psychiatry, 45, 111, 10.1001/archpsyc.1988.01800260015002 · DOI · Paper page
  46. Bowden, 1994, Efficacy of divalproex vs lithium and placebo in the treatment of mania. The Depakote Mania Study Group., JAMA, 271, 918, 10.1001/jama.1994.03510360044034 · DOI · Paper page
  47. Lambert, 1987, Utilisation de valpromise en therapeutique psychiatrique., Encephale, 8, 367
  48. Gyulai, 2003, Maintenance efficacy of divalproex in the prevention of bipolar depression., Neuropsychopharmacol, 28, 1374, 10.1038/sj.npp.1300190 · DOI
  49. Hussar, 1962, Effect of tranquilizers on medical morbidity and mortality in a mental hospital., JAMA, 179, 682, 10.1001/jama.1962.03050090010002 · doi:10.1001/jama.1962.03050090010002
  50. Beisser, 1961, A study of suicides in a mental hospital., Dis Nerv Syst, 22, 365
  51. Winokur, 1975, The Iowa 500: suicide in mania, depression, and schizophrenia., Am J Psychiatry, 132, 650, 10.1176/ajp.132.6.650 · DOI
  52. Kerwin, 2003, Preventing suicide Correspondence., Br J Psychiatry, 182, 366, 10.1192/bjp.182.4.366 · DOI
  53. Roy, 1992, Marked reduction in indexes of dopamine metabolism among patients with depression who attempt suicide., Arch Gen Psychiatry, 49, 447, 10.1001/archpsyc.1992.01820060027004 · DOI
  54. Caldwell, 1992, Schizophreniaa high risk factor for suicide: clues to risk reduction., Suicide Life Threat Behav, 22, 479, 10.1111/j.1943-278X.1992.tb01040.x · DOI
  55. Altamaura, 2003, Clinical variables related to suicide attempts in schizophrenic patients: a retrospective study., Schizophr Res, 60, 47, 10.1016/S0920-9964(02)00164-0 · DOI
  56. Heila, 1999, Suicide victims with schizophrenia in different treatment phases and adequacy of antipsychotic medication., J Clin Psychiatry, 60, 200, 10.4088/JCP.v60n0311 · DOI
  57. Meltzer, 2001, Treatment of suicidality in schizophrenia., Ann NY Acad Sci, 932, 44, 10.1111/j.1749-6632.2001.tb05797.x · DOI
  58. Meltzer, 1995, Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk-benefit assessment., Am J Psychiatry, 152, 183, 10.1176/ajp.152.2.183 · DOI · Paper page
  59. Shear, 1983, Suicide associated with akathisia and depot fluphenazine treatment., J Clin Psychopharmacol, 3, 235, 10.1097/00004714-198308000-00006 · DOI
  60. Blum, 1980, Patients at risk of developing severe side effects from depot fluphenazine treatment., Am J Psychiatry, 137, 254, 10.1176/ajp.137.2.254 · doi:10.1176/ajp.137.2.254
  61. Drake, 1985, Suicide attempts associated with akathisia., Am J Psychiatry, 142, 499, 10.1176/ajp.142.4.499 · DOI
  62. Weiden, 1985, Akathisia from prochlorperazine Letter., JAMA, 253, 635, 10.1001/jama.1985.03350290037017 · DOI
  63. Schulte, 1985, Homicide and suicide associated with akathisia and haloperidol., Am J Forensic Psychiatry, 6, 3
  64. Shaw, 1986, A case of suicidal and homicidal ideation and akathisia in a double-blind neuroleptic crossover study Letter., J Clin Psychopharmacol, 6, 196, 10.1097/00004714-198606000-00024 · DOI
  65. Planansky, 1971, The occurrence and characteristics of suicidal preoccupation and acts in schizophrenia., Acta Psychiatr Scand, 47, 473, 10.1111/j.1600-0447.1971.tb03704.x · DOI
  66. van Putten, 1974, Phenothiazine-induced decompensation., Arch Gen Psychiatry, 30, 102, 10.1001/archpsyc.1974.01760070080012 · DOI
  67. van Putten, 1975, The many faces of akathisia., Compr Psychiatry, 16, 43, 10.1016/0010-440X(75)90019-X · DOI
  68. Rifkin, 1975, Akinesia: a poorly recognized drug-induced extrapyramidal behavior disorder., Arch Gen Psychiatry, 32, 672, 10.1001/archpsyc.1975.01760230138011 · DOI · Paper page
  69. Siris, 1987, Adjunctive imipramine in the treatment of postpsychotic depression: a controlled trial., Arch Gen Psychiatry, 44, 533, 10.1001/archpsyc.1987.01800180043008 · DOI
  70. Hogan, 1983, Pharmacotherapy and suicide risk in schizophrenia., Can J Psychiatry, 28, 277, 10.1177/070674378302800407 · doi:10.1177/070674378302800407
  71. Cheng, 1990, Risk factors of suicide among schizophrenics., Acta Psychiatr Scand, 81, 220, 10.1111/j.1600-0447.1990.tb06484.x · DOI
  72. Montout, 2002, Neuroleptics and mortality in schizophrenia: prospective analysis of deaths in a French cohort of schizophrenic patients., Schizophr Res, 57, 146, 10.1016/S0920-9964(01)00325-5 · DOI
  73. Montgomery, 1997, Suicide and antidepressants., Ann NY Acad Sci, 836, 329, 10.1111/j.1749-6632.1997.tb52368.x · DOI
  74. Taiminen, 1993, Effect of psychopharmacotherapy on suicide risk in psychiatric inpatients., Acta Psychiatr Scand, 87, 45, 10.1111/j.1600-0447.1993.tb03328.x · DOI
  75. Taiminen, 1994, Antipsychotic medication and suicide risk among schizophrenic and paranoid inpatients. A controlled retrospective study., Acta Psychiatr Scand, 90, 247, 10.1111/j.1600-0447.1994.tb01588.x · DOI
  76. Cohen, 1964, Tranquilizers and suicide in the schizophrenic patient., Arch Gen Psychiatry, 11, 312, 10.1001/archpsyc.1964.01720270084010 · DOI
  77. Roy, 1982, Suicide in chronic schizophrenia., Br J Psychiatry, 141, 171, 10.1192/bjp.141.2.171 · DOI · Paper page
  78. Wilkinson, 1984, A clinical and epidemiological survey of parasuicide and suicide in Edinburgh schizophrenics., Psychol Med, 14, 899, 10.1017/S0033291700019863 · DOI
  79. Palmer, 1999, Do antipsychotic medications decrease the risk of suicide in patients with schizophrenia., J Clin Psychiatry, 60, 100
  80. Bebbington, 1995, The content and context of compliance., Int Clin Psychopharmacol, 9, 41, 10.1097/00004850-199501005-00008 · DOI · Paper page
  81. Heila, 1999, Suicide victims with schizophrenia in different treatment phases and adequacy of antipsychotic medication., J Clin Psychiatry, 60, 200, 10.4088/JCP.v60n0311 · DOI
  82. Johnson, 1983, The discontinuance of maintenance neuroleptic therapy in chronic schizophrenic patients: drug and social consequences., Acta Psychiatr Scand, 67, 339, 10.1111/j.1600-0447.1983.tb00351.x · DOI
  83. Montgomery, 1992, Pharmacotherapy in the prevention of suicidal behavior., J Clin Psychopharmacol, 12, 27S, 10.1097/00004714-199204001-00006 · doi:10.1097/00004714-199204001-00006
  84. Soloff, 1986, Progress in pharmacotherapy of borderline disorders. A double blind study of amitriptyline, haloperidol and placebo., Arch Gen Psychiatry, 43, 691, 10.1001/archpsyc.1986.01800070081010 · DOI
  85. Battaglia, 1999, Structured diagnostic assessment and depot fluphenazine treatment of multiple suicide attempters in the emergency department., Int Clin Psychopharmacol, 14, 361, 10.1097/00004850-199911000-00007 · DOI
  86. Spivak, 1997, Reduction of aggressiveness and impulsiveness during clozapine treatment in chronic neuroleptic-resistant schizophrenic patients., Clin Neuropharmacol, 20, 442, 10.1097/00002826-199710000-00009 · DOI
  87. Khan, 2001, Symptom reduction and suicide risk among patients treated with placebo in antipsychotic clinical trials: an analysis of the Food and Drug Administration database., Am J Psychiatry, 158, 1449, 10.1176/appi.ajp.158.9.1449 · DOI
  88. Storosum, 2003, Suicide risk in placebo vs active treatment in placebo-controlled trials for schizophrenia., Arch Gen Psychiatry, 60, 365, 10.1001/archpsyc.60.4.365 · DOI
  89. Walker, 1997, Mortality in current and former users of clozapine., Epidemiology, 8, 671, 10.1097/00001648-199711000-00014 · DOI
  90. Reid, 1998, Suicide prevention effects associated with clozapine therapy in schizophrenia and schizoaffective disorder., Psychiatr Serv, 49, 1029, 10.1176/ps.49.8.1029 · DOI
  91. Munro, 1999, Active monitoring of 12,760 clozapine recipients in the UK and Ireland: beyond pharmacovigilance., Br J Psychiatry, 175, 576, 10.1192/bjp.175.6.576 · DOI · Paper page
  92. Duggan, 2003, Modelling the impact of clozapine on suicide in patients with treatment-resistant schizophrenia., Brit J Psychiatry, 182, 505, 10.1192/bjp.182.6.505 · DOI
  93. Sernyak, 2001, Impact of clozapine on completed suicide., Am J Psychiatry, 158, 931, 10.1176/appi.ajp.158.6.931 · DOI
  94. Meltzer, 2002, Clozapine and suicide Letter., Am J Psychiatry, 159, 323, 10.1176/appi.ajp.159.2.323-a · doi:10.1176/appi.ajp.159.2.323-a
  95. Ertugrul, 2002, Clozapine and suicide Letter., Am J Psychiatry, 159, 323, 10.1176/appi.ajp.159.2.323 · doi:10.1176/appi.ajp.159.2.323
  96. Vangala, 1999, Clozapine associated with decreased suicidality in bipolar disorder: a case report., Bipolar Disord, 2, 123, 10.1034/j.1399-5618.1999.010210.x · DOI
  97. Frye, 1998, Clozapine in bipolar disorder: treatment implications for atypical antipsychotics., J Affect Disord, 48, 91, 10.1016/S0165-0327(97)00160-2 · DOI
  98. Nahunek, 1973, Clinical experience with clozapine in endogenous depression Letter., Activ Nerv Super, 15, 102
  99. Ranjan, 1996, Acute and long term effectiveness of clozapine in treatment-resistant psychotic depression., Biol Psychiatry, 40, 253, 10.1016/0006-3223(95)00305-3 · DOI
  100. Suppes, 1999, Clinical outcome in a randomized 1-year trial of clozapine versus treatment as usual for patients with treatment-resistant illness and a history of mania., Am J Psychiatry, 156, 1164, 10.1176/ajp.156.8.1164 · DOI · Paper page
  101. Spivak, 2003, The effects of clozapine versus haloperidol on measures of impulsive aggression and suicidality in chronic schizophrenia patients: an open, nonrandomized, 6-month study., J Clin Psychiatry, 64, 755, 10.4088/JCP.v64n0703 · DOI
  102. Benedetti, 1998, Low-dose clozapine in acute and continuation treatment of severe borderline personality disorder., J Clin Psychiatry, 59, 103, 10.4088/JCP.v59n0302 · DOI
  103. Zhang, 2000, Synergistic effects of olanzapine and other antipsychotic agents in combination with fluoxetine on norepinephrine and dopamine release in rat prefrontal cortex., Neuropsychopharmacology, 23, 250, 10.1016/S0893-133X(00)00119-6 · DOI
  104. Shelton, 2001, A novel augmentation strategy for treating resistant major depression., Am J Psychiatry, 158, 131, 10.1176/appi.ajp.158.1.131 · DOI · Paper page
  105. Tran, 1997, Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders., J Clin Psychiatry, 17, 407
  106. Glazer, 1998, Formulary decisions and health economics., J Clin Psychiatry, 59, 23
  107. Beasley, 1998, The influence of pharmacotherapy on self-directed and externally-directed aggression in schizophrenia Abstract., Schizophr Res, 29, 28, 10.1016/S0920-9964(97)88362-4 · DOI
  108. Muller-Siecheneder, 1998, Risperidone versus haloperidol and amitriptyline in the treatment of patients with a combined psychotic and depressive syndrome., J Clin Psychopharmacol, 18, 111, 10.1097/00004714-199804000-00003 · DOI
  109. Viner, 2003, Low-dose risperidone augmentation of antidepressants in nonpsychotic depressive disorders with suicidal ideation., J Clin Psychopharmacol, 23, 104, 10.1097/00004714-200302000-00019 · DOI
  110. Margolese, 2002, Depression and dysphoria in adult and adolescent patients with Tourettes disorder treated with risperidone., J Clin Psychiatry, 63, 1040, 10.4088/JCP.v63n1115 · DOI
  111. Keck, 2001, Ziprasidone Study Group, Ziprasidone in the short-term treatment of patients with schizoaffective disorder: results from two double-blind, placebo-controlled, multicenter studies., J Clin Psychopharmacol, 21, 27, 10.1097/00004714-200102000-00007 · DOI
  112. 2003, , Buckley P., Jones A M., Greenwood MR. Differential effect of quetiapine on partially responsive schizophrenia., J Psychopharmacol, 17, 210, 10.1177/0269881103017002010 · DOI
  113. Kessler, 1994, Lifetime and 12-month prevalence of DSM-IIII-R psychiatric disorders in the United States: results from the National Comorbidity Survey., Arch Gen Psychiatry, 51, 8, 10.1001/archpsyc.1994.03950010008002 · DOI · Paper page
  114. Matthews, 2000, Risk of suicidality in depression with serotonergic antidepressants., Ann Clin Psychiatry, 12, 43, 10.3109/10401230009147086 · doi:10.3109/10401230009147086
  115. Coccaro, 1997, Fluoxetine and impulsive aggressive behavior in personality-disordered subjects., Arch Gen Psychiatry, 54, 1081, 10.1001/archpsyc.1997.01830240035005 · DOI · Paper page
  116. Montgomery, 1995, Reduction of suicidal thoughts with paroxetine in comparison with reference antidepressants and placebo., Eur Neuropsychopharmacol, 5, 5, 10.1016/0924-977X(94)00131-T · DOI
  117. Beasley, 2000, Adverse events and treatment discontinuations in clinical trials of fluoxetine in major depressive disorder: an updated meta-analysis., Clin Ther, 22, 1319, 10.1016/S0149-2918(00)83028-3 · DOI
  118. Letizia, 1996, Suicidal risk during controlled clinical investigations of fluvoxamine., J Clin Psychiatry, 59, 415
  119. Tollefson, 1993, Evaluation of suicidality during pharmacologic treatment of mood and nonmood disorders., Ann Clin Psychiatry, 5, 209, 10.3109/10401239309148820 · DOI
  120. Wernicke, 1997, Fluoxetine and concomitant centrally acting medication use during clinical trials of depression: the absence of an effect related to agitation and suicidal behavior., Depress Anxiety, 6, 31, 10.1002/(SICI)1520-6394(1997)6:1<31::AID-DA5>3.0.CO;2-8 · DOI
  121. Muijen, 1988, A comparative clinical trial of fluoxetine, mianserin and placebo in depressed patients., Acta Psychiatr Scand, 78, 384, 10.1111/j.1600-0447.1988.tb06353.x · DOI
  122. Georgotas, 1987, Response of depressive symptoms to nortriptyline, phenelzine and placebo., Br J Psychiatry, 151, 102, 10.1192/bjp.151.1.102 · DOI
  123. Verkes, 1998, Reduction of paroxetine of suicidal behavior in patients with repeated suicide attempts but not major depression., Am J Psychiatry, 155, 543, 10.1176/ajp.155.4.543 · DOI
  124. Cornelius, 1991, A preliminary trial of fluoxetine in refractory borderline patients., J Clin Psychopharmacol, 11, 116, 10.1097/00004714-199104000-00008 · DOI
  125. Markovitz, 1991, Fluoxetine in the treatment of borderline and schizotypal personality disorders., Am J Psychiatry, 148, 1064, 10.1176/ajp.148.8.1064 · DOI
  126. Montgomery, 1983, The prevention of recurrent suicidal acts., Br J Clin Pharmacol, 15, 183S, 10.1111/j.1365-2125.1983.tb05864.x · DOI
  127. Soloff, 1986, Parodoxical effects of amitriptyline on borderline patients., Am J Psychiatry, 143, 1603, 10.1176/ajp.143.12.1603 · DOI
  128. Khan, 2000, Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: an analysis of the Food and Drug Administration database., Arch Gen Psychiatry, 57, 311, 10.1001/archpsyc.57.4.311 · DOI · Paper page
  129. Khan, 2003, Suicide rates in clinical trials of SSRIs, other antidepressants, and placebo: analysis of FDA reports., Am J Psychiatry, 160, 790, 10.1176/appi.ajp.160.4.790 · DOI · Paper page
  130. Beasley, 1991, Fluoxetine and suicide: a meta-analysis of controlled trials of treatment for depression., BMJ, 303, 685, 10.1136/bmj.303.6804.685 · DOI · Paper page
  131. Beasley, 1991, Fluoxetine not associated with suicidality in international controlled clinical trials in depression., Clin Res, 39, 767A
  132. Wheadon, 1992, Lack of association between fluoxetine and suicidality in bulimia nervosa., J Clin Psychiatry, 53, 235
  133. Goldstein, 1999, Analyses of suicidality in double-blind, placebo-controlled trials of pharmacotherapy for weight reduction., J Clin Psychiatry, 54, 309
  134. Beasley, 1992, Fluoxetine: no association with suicidality in obsessive compulsive disorder., J Affect Disord, 24, 1, 10.1016/0165-0327(92)90054-A · DOI
  135. Leon, 1999, Prospective study of fluoxetine treatment and suicidal behavior in affectively ill subjects., Am J Psychiatry, 156, 195, 10.1176/ajp.156.2.195 · DOI
  136. Tec, 1968, The treatment of enuresis with imipramine., Am J Psychiatry, 125, 266, 10.1176/ajp.125.2.266 · doi:10.1176/ajp.125.2.266
  137. Rampling, 1978, Aggression: a paradoxical response to tricyclic antidepressants., Am J Psychiatry, 135, 117, 10.1176/ajp.135.1.117 · DOI
  138. Damluji, 1998, Paradoxical worsening of depressive symptomatology caused by antidepressants., J Clin Psychopharmacol, 6, 77
  139. Teicher, 1990, Emergence of intense suicidal preoccupation during fluoxetine treatment., Am J Psychiatry, 147, 207, 10.1176/ajp.147.2.207 · DOI · Paper page
  140. Dasgupta, 1990, Additional cases of suicidal ideation associated with fluoxetine Letter., Am J Psychiatry, 147, 1570, 10.1176/ajp.147.11.1570 · doi:10.1176/ajp.147.11.1570
  141. Wirshing, 1992, Fluoxetine, akathisia and suicidality: is there a causal connection., Arch Gen Psychiatry, 49, 580, 10.1001/archpsyc.1992.01820070074012 · DOI
  142. Masand, 1991, Suicidal ideation related to fluoxetine treatment Letter., N Engl J Med, 324, 420, 10.1056/NEJM199102073240616 · DOI
  143. Rothschild, 1991, Re-exposure to fluoxetine after serious suicide attempts by three patients: the role of akathisia., J Clin Psychiatry, 52, 491
  144. Vorstman, 2001, SSRIs associated with behavioral activation and suicidal ideation., J Am Acad Child Adol Psychiatry, 40, 1364, 10.1097/00004583-200112000-00004 · DOI
  145. Waechter, 2003, Paroxetine must not be given to patients under 18., BMJ, 326, 1282, 10.1136/bmj.326.7402.1282-b · DOI
  146. Abbott, 2003, British panel bans use of antidepressant in treat children., Nature, 423, 792, 10.1038/423792a · DOI
  147. Lindgren, 1987, Effects of serotonin receptor agonists and antagonists on offensive aggression in mice., Aggressive Behav, 13, 87, 10.1002/1098-2337(1987)13:2<87::AID-AB2480130205>3.0.CO;2-0 · doi:10.1002/1098-2337(1987)13:2<87::aid-ab2480130205>3.0.co;2-0
  148. Mann, 1991, The emergence of suicidal ideation and behavior during antidepressant pharmacotherapy., Arch Gen Psychiatry, 48, 1027, 10.1001/archpsyc.1991.01810350067011 · DOI
  149. Mann, 1989, Evidence for the 5-HT hypothesis of suicide: a review of post-mortem studies., Br J Psychiatry, 155, 7, 10.1192/S000712500029171X · DOI
  150. Hansen, 2001, Drug induced akathisia, suicidal ideation and its treatment in the elderly., Int J Geriatr Psychiatry, 16, 230, 10.1002/1099-1166(200102)16:2<231::AID-GPS303>3.0.CO;2-Y · doi:10.1002/1099-1166(200102)16:2<231::aid-gps303>3.0.co;2-y
  151. Lipinski, 1989, Fluoxetine induced akathisia: clinical and theoretical implications., J Clin Psychiatry, 50, 339
  152. Zubenko, 1987, Anti-depressant-related akathisia., J Clin Psychopharmacol, 7, 254, 10.1097/00004714-198708000-00009 · DOI
  153. Hamilton, 1992, Akathisia, suicidality and fluoxetine., J Clin Psychiatry, 53, 401
  154. Lane, 1998, SSRI-induced EPS and akathisia: implications for treatment., J Psychopharmacol, 12, 192, 10.1177/026988119801200212 · DOI
  155. Popli, 1993, Polypharmacy, akathisia and associated suicide attempts., Depression, 1, 53, 10.1002/depr.3050010111 · doi:10.1002/depr.3050010111
  156. Tollefson, 1994, Absence of a relationship between adverse events and suicidality during pharmacotherapy for depression., J Clin Psychopharmacol, 14, 163, 10.1097/00004714-199406000-00003 · DOI
  157. Rouillon, 1989, Prophylactic efficacy of maprotiline on relapses of unipolar depression., Encephale, 15, 527
  158. Fava, 1991, Suicidality and fluoxetine: is there a relationship., J Clin Psychiatry, 52, 108
  159. Warshaw, 1996, The relationship between fluoxetine use and suicidal behavior in 654 subjects with anxiety disorders., J Clin Psychiatry, 57, 158
  160. Buchholtz-Hansen, 1993, Mortality in major affective disorder: relationship to subtype of depression. Danish University Antidepressant Group., Acta Psychiatr Scand, 87, 329, 10.1111/j.1600-0447.1993.tb03381.x · DOI
  161. Dunbar, 1991, A comparison of paroxetine, imipramine and placebo in depressed outpatients., Br J Psychiatry, 159, 394, 10.1192/bjp.159.3.394 · DOI
  162. Kapur, 1992, Antidepressant medications and the relative risk of suicide attempt and suicide., JAMA, 268, 3441, 10.1001/jama.1992.03490240049035 · DOI · Paper page
  163. Jick, 1995, Antidepressants and suicide., BMJ, 310, 215, 10.1136/bmj.310.6974.215 · DOI
  164. Fischer, 1993, Postmarketing surveillance by patient self-monitoring: trazodone versus fluoxetine., J Clin Psychopharmacol, 13, 235
  165. Derby, 1992, Antidepressant drugs and suicide., J Clin Psychopharmacol, 12, 235, 10.1097/00004714-199208000-00004 · DOI
  166. Montgomery, 1978, Differential effects on suicidal ideation of mianserin, maprotiline and amitriptyline., Br J Clin Pharmacol, 5, 77S, 10.1111/j.1365-2125.1978.tb04580.x · DOI · Paper page
  167. Oquendo, 1999, Inadequacy of antidepressant treatment for patients with major depression who are at risk for suicidal behavior., Am J Psychiatry, 156, 190, 10.1176/ajp.156.2.190 · DOI · Paper page
  168. Oquendo, 2002, Adequacy of antidepressant treatment after discharge and the occurrence of suicidal acts in major depression: a prospective study., Am J Psychiatry, 159, 1746, 10.1176/appi.ajp.159.10.1746 · DOI
  169. Isacsson, 1994, Antidepressants, depression and suicide: an analysis of the San Diego study., J Affect Disord, 32, 277, 10.1016/0165-0327(94)90092-2 · DOI
  170. Isacsson, 1997, The utilization of antidepressantsa key issue in the prevention of suicide: an analysis of 5281 suicides in Sweden during the period of 1992-1994., Acta Psychiatr Scand, 96, 94, 10.1111/j.1600-0447.1997.tb09912.x · DOI
  171. Isacsson, 1999, Psychotics and suicide prevention: implications from toxicological screening of 5281 suicides in Sweden 1992-1994., Br J Psychiatry, 174, 259, 10.1192/bjp.174.3.259 · DOI
  172. Andersen, 2001, Psychopharmacological treatment and psychiatric morbidity in 390 cases of suicide with special focus on affective disorders., Acta Psychiatr Scand, 104, 458, 10.1034/j.1600-0447.2001.00191.x · DOI
  173. Henriksson, 2001, Suicides are seldom prescribed antidepressants: findings from a prospective prescription database in Jamtland county, Sweden, 1985-95., Acta Psychiatr Scand, 103, 301, 10.1034/j.1600-0447.2001.00276.x · DOI
  174. Marzuk, 1995, Use of prescription psychotropic drugs among suicide victims in New York City., Am J Psychiatry, 152, 1520, 10.1176/ajp.152.10.1520 · DOI
  175. Suominen, 1998, Inadequate treatment for major depression both before and after attempted suicide., Am J Psychiatry, 155, 1778, 10.1176/ajp.155.12.1778 · DOI
  176. Wolf, 1996, How to interpret findings on mortality of long-term lithium-treated manic-depressive patients Critique of different methodological approaches., J Affect Disord, 39, 127, 10.1016/0165-0327(96)00032-8 · DOI
  177. Charney, 2002, National Depressive and Manic-Depressive Association consensus statement on the use of placebo in clinical trials of mood disorders., Arch Gen Psychiatry, 59, 262, 10.1001/archpsyc.59.3.262 · DOI

Cited by

See all 32

Metadata

Authors
Ernst, C. L., & Goldberg, J. F.
Venue
Harvard Review of Psychiatry
Publisher
Ovid Technologies (Wolters Kluwer Health)
Published
2004-01
Volume
12
Issue
1
Pages
14-41
ISSN
1067-3229
DOI
10.1080/10673220490425924
Cited by
32
References
5
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Antisuicide Properties of Psychotropic Drugs: A Critical Review. https://app.cochat.ai/papers/10.1080/10673220490425924
The paper
Ernst, C. L., & Goldberg, J. F. (2004). Antisuicide Properties of Psychotropic Drugs: A Critical Review. Harvard Review of Psychiatry. https://doi.org/10.1080/10673220490425924

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.